Viridian Therapeutics promotes Seth Harmon to CFO effective Jan 1, 2025

Viridian Therapeutics, Inc.\DE

Seth Harmon, previously SVP of Finance and Accounting and Principal Financial Officer, appointed CFO effective Jan 1, 2025.
New base salary of $480,000 and target bonus of 40% of base salary.
Received equity awards: stock option with grant date value of $1,662,000 and RSUs with grant date value of $554,000.
Harmon's prior roles include CFO of BioNTech US subsidiary and VP of Finance at Neon Therapeutics.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Seth Harmon

Chief Financial Officer

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2025-01-01
Filed: January 10, 2025, 6:59 PM ET

On January 7, 2025, the Board of Directors of Viridian Therapeutics, Inc. (the “Company”) appointed Seth Harmon to serve as the Chief Financial Officer of the Company effective as of January 1, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Seth Harmon was appointed as Chief Financial Officer at Viridian Therapeutics, Inc.\DE.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On January 7, 2025, the Board of Directors of Viridian Therapeutics, Inc. (the “Company”) appointed Seth Harmon to serve as the Chief Financial Officer of the Company effective as of January 1, 2025.

View on SEC.gov

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-25-004435

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.